Niamat Ali Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Niamat Ali Khan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Johannes Swinnen
Laboratory of Lipid Metabolism and Cancer, Department of Oncology, KU Leuven, 3000 Leuven, Belgium
3 shared publications Jonas Dehairs
KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium
3 shared publicationsEtienne Waelkens
Laboratory of Protein Phosphorylation and Proteomics, KU Leuven-University of Leuven, B-3000 Leuven, Belgium
2 shared publicationsFrank Vanderhoydonc
KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium
2 shared publications- Maria Mercedes Binda
Department Obstetrics and Gynaecology, Katholieke University Leuven, 3000 Leuven, Belgium
2 shared publications Muralidhararao Bagadi
KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium
2 shared publications
Latest Publications
- Open Access
- 4 February 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (9) , 9975-9992
Identification of drugs that restore primary cilium expression in cancer cells
Identification of drugs that restore primary cilium expression in cancer cells
- 4 February 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (9) , 9975-9992
Open AccessIdentification of drugs that restore primary cilium expression in cancer cells
Identification of drugs that restore primary cilium expression in cancer cells
- Open Access
- 13 July 2015
- Published by Springer Nature in Cilia
- Vol. 4 (1) , P57
Identification of ciliogenic compounds using pancreatic cancer cells as a screening model
- 13 July 2015
- Published by Springer Nature in Cilia
- Vol. 4 (1) , P57
Open AccessIdentification of ciliogenic compounds using pancreatic cancer cells as a screening model
- Open Access
- 15 June 2015
- Published by American Society for Cell Biology (ASCB) in Molecular Biology of the Cell
- Vol. 26 (12) , 2321-2332
Primary cilium suppression by SREBP1c involves distortion of vesicular trafficking by PLA2G3
Distortion of primary cilia formation is increasingly recognized as a key event in many human pathologies. One of the underlying mechanisms involves aberrant activation of the lipogenic transcription factor Sterol Regulatory Element–binding Protein 1c (SREBP1c), as observed in cancer cells. To gain more insight into the molecular pathways by which SREBP1c suppresses primary ciliogenesis, we searched for overlap between known ciliogenesis regulators and targets of SREBP1. One of the candidate genes that was consistently upregulated in cellular models of SREBP1c-induced cilium repression was Phospholipase A2 group III (PLA2G3), a phospholipase that hydrolyses the sn-2 position of glycerophospholipids. Use of RNA interference and a chemical inhibitor of PLA2G3 rescued SREBP1c-induced cilium repression. Cilium repression by SREBP1c and PLA2G3 involved alterations in endosomal recycling and vesicular transport toward the cilium as revealed by aberrant transferrin and Rab11 localization and was largely mediated by an increase in lysophosphatidylcholine and lysophosphatidylethanolamine levels. Together, these findings indicate that aberrant activation of SREBP1c suppresses primary ciliogenesis by PLA2G3-mediated distortion of vesicular trafficking and suggest that PLA2G3 is a novel potential target to normalize ciliogenesis in SREBP1c-overexpressing cells, including cancer cells.
- 15 June 2015
- Published by American Society for Cell Biology (ASCB) in Molecular Biology of the Cell
- Vol. 26 (12) , 2321-2332
Open AccessPrimary cilium suppression by SREBP1c involves distortion of vesicular trafficking by PLA2G3
Distortion of primary cilia formation is increasingly recognized as a key event in many human pathologies. One of the underlying mechanisms involves aberrant activation of the lipogenic transcription factor Sterol Regulatory Element–binding Protein 1c (SREBP1c), as observed in cancer cells. To gain more insight into the molecular pathways by which SREBP1c suppresses primary ciliogenesis, we searched for overlap between known ciliogenesis regulators and targets of SREBP1. One of the candidate genes that was consistently upregulated in cellular models of SREBP1c-induced cilium repression was Phospholipase A2 group III (PLA2G3), a phospholipase that hydrolyses the sn-2 position of glycerophospholipids. Use of RNA interference and a chemical inhibitor of PLA2G3 rescued SREBP1c-induced cilium repression. Cilium repression by SREBP1c and PLA2G3 involved alterations in endosomal recycling and vesicular transport toward the cilium as revealed by aberrant transferrin and Rab11 localization and was largely mediated by an increase in lysophosphatidylcholine and lysophosphatidylethanolamine levels. Together, these findings indicate that aberrant activation of SREBP1c suppresses primary ciliogenesis by PLA2G3-mediated distortion of vesicular trafficking and suggest that PLA2G3 is a novel potential target to normalize ciliogenesis in SREBP1c-overexpressing cells, including cancer cells.
- Open Access
- 3 June 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (25) , 21240-21254
p53 attenuates AKT signaling by modulating membrane phospholipid composition
P53 attenuates AKT signaling by modulating membrane phospholipid composition p53 attenuates AKT signaling by modulating membrane phospholipid composition
- 3 June 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (25) , 21240-21254
Open Accessp53 attenuates AKT signaling by modulating membrane phospholipid composition
P53 attenuates AKT signaling by modulating membrane phospholipid composition p53 attenuates AKT signaling by modulating membrane phospholipid composition